Santen Pharmaceutical (OTCMKTS:SNPHY) Sees Large Volume Increase – Still a Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw unusually-high trading volume on Thursday . Approximately 41,639 shares changed hands during trading, an increase of 155% from the previous session’s volume of 16,329 shares.The stock last traded at $10.7390 and had previously closed at $10.4684.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Santen Pharmaceutical Stock Performance

The firm has a market capitalization of $3.35 billion and a PE ratio of 0.10. The company’s fifty day moving average price is $11.03 and its two-hundred day moving average price is $10.66.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.